Stock EW EDWARDS LIFESCIENCES CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Edwards Lifesciences Corporation

Equities

EW

US28176E1082

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-19 pm EDT 		5-day change 1st Jan Change
85.94 USD -0.59% Intraday chart for Edwards Lifesciences Corporation -4.81% +12.71%
Apr. 17 Baird Adjusts Edwards Lifesciences Price Target to $102 From $100 MT
Apr. 17 Leerink Partners Adjusts Edwards Lifesciences' Price Target to $93 From $96, Keeps Market Perform Rating MT

Evolution of the average Target Price on Edwards Lifesciences Corporation

Price target over the last 5 years

History of analyst recommendation changes

a731b5bb5.CKulXfZnEjZaMKwkhYvHQsCQi-plUuhfNzdq05pFonk.a_LEGbwmQA4jRN118vqwdK3a8aJVY9AIDlxSg9sazhFjzJAPkDJhQ2NS6Q~fd77cdb394cb098b8915f6b39d01aa21

Analyst Recommendations on Edwards Lifesciences Corporation

Baird Adjusts Edwards Lifesciences Price Target to $102 From $100 MT
Leerink Partners Adjusts Edwards Lifesciences' Price Target to $93 From $96, Keeps Market Perform Rating MT
ANALYST RECOMMENDATIONS : AMD, Colgate, Fair Isaac, Tyson Foods, AstraZeneca Our Logo
Zacks Investment Research Adjusts Price Target on Edwards Lifesciences to $95 From $97 MT
Truist Securities Adjusts Edwards Lifesciences Price Target to $105 From $97, Buy Rating Kept MT
RBC Raises Price Target on Edwards Lifesciences to $101 From $95, Keeps Outperform Rating MT
Mizuho Securities Adjusts Price Target on Edwards Lifesciences to $105 From $95, Maintains Buy Rating MT
Edwards Lifesciences Insider Sold Shares Worth $1,154,142, According to a Recent SEC Filing MT
Edwards Lifesciences Insider Sold Shares Worth $1,329,472, According to a Recent SEC Filing MT
Edwards Lifesciences Insider Sold Shares Worth $2,712,418, According to a Recent SEC Filing MT
Citigroup Raises Price Target on Edwards Lifesciences to $98 From $90, Maintains Neutral Rating MT
Edwards Lifesciences Insider Sold Shares Worth $688,423, According to a Recent SEC Filing MT
Morgan Stanley Lifts Price Target on Edwards Lifesciences to $103 From $95, Sees 'Upside Risk' Amid Transcatheter Mitral & Tricuspid Therapies, Overweight Rating Kept MT
Oppenheimer Raises Edwards Lifesciences Price Target to $100 From $93, Maintains Outperform Rating MT
BofA Securities Upgrades Edwards Lifesciences to Buy From Neutral, Adjusts Price Target to $105 From $97 MT
UBS Adjusts Edwards Lifesciences Price Target to $92 From $84, Maintains Neutral Rating MT
Canaccord Genuity Adjusts Price Target on Edwards Lifesciences to $86 From $81, Maintains Hold Rating MT
Fed officials fail to convince investors, who are focused on earnings Our Logo
Oppenheimer Adjusts Edwards Lifesciences Price Target to $93 From $90, Maintains Outperform Rating MT
Jefferies Adjusts Price Target on Edwards Lifesciences to $102 From $90, Keeps Buy Rating MT
Mizuho Adjusts Price Target on Edwards Lifesciences to $95 From $85, Keeps Buy Rating MT
Baird Adjusts Price Target on Edwards Lifesciences to $100 From $85, Keeps Outperform Rating MT
JPMorgan Adjusts Price Target on Edwards Lifesciences to $105 From $84, Keeps Overweight Rating MT
Truist Adjusts Price Target on Edwards Lifesciences to $97 From $84, Keeps Buy Rating MT
Stifel Adjusts Price Target on Edwards Lifesciences to $83 From $70, Keeps Hold Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
85.94 USD
Average target price
94.48 USD
Spread / Average Target
+9.94%
High Price Target
105 USD
Spread / Highest target
+22.18%
Low Price Target
72 USD
Spread / Lowest Target
-16.22%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Edwards Lifesciences Corporation

Baird
Leerink Partners
Zacks Investment Research
Truist Securities
RBC Capital Markets
Mizuho Securities
Citigroup
Morgan Stanley
Oppenheimer
BofA Securities
UBS
Canaccord Genuity
Stifel Nicolaus
Jefferies & Co.
JPMorgan Chase
Wells Fargo Securities
Evercore ISI
Wolfe Research
Deutsche Bank Securities
TD Cowen
Piper Sandler
Barclays
Bernstein
Raymond James
Goldman Sachs
Cowen
SVB Leerink
Credit Suisse
Atlantic Equities

Ratings for Edwards Lifesciences Corporation

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. EW Stock
  4. Consensus Edwards Lifesciences Corporation